# Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)

> **NCT02341911** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 150 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Gemcitabine,cisplatin
- **DRUG:** Gemcitabine,carboplatin

## Key facts

- **NCT ID:** NCT02341911
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2022-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02341911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02341911, "Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)". Retrieved via MORVS 2026-10-16 from https://api.morvs.ai/clinical/NCT02341911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*